Fig. 7: Patient survival outcomes improve in MSLN high tumors with MSS status across all immunotherapeutic treatment strategies. | Cancer Gene Therapy

Fig. 7: Patient survival outcomes improve in MSLN high tumors with MSS status across all immunotherapeutic treatment strategies.

From: Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer

Fig. 7

Patient insurance claims data provided to Caris Life Sciences were used to generate Kaplan–Meier curves via the CODEai™ data portal. Curves depict survival from the time of tissue collection or first treatment to last contact for the entire cohort (A) and MSS cohort (B) of CRC patients by the lowest 25% MSLN expression quartile (blue/cohort 1) and highest 25% MSLN expression quartile (red/cohort 2) across several therapeutic interventions.

Back to article page